Coya Therapeutics announces $46.8M cash, runway into H2 2027, ALSTARS readout Q1 2027

Coya Therapeutics, Inc.

Cash balance of $46.8M as of Dec 31, 2025 (unaudited), with projected runway into second half of 2027.
Company expects topline data readout from ALSTARS Phase 2 trial in first quarter of 2027.
Updates conveyed in letter to stockholders dated January 20, 2026.

item 8.01

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-016017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.